EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun und 12 weitere

Advanced Science · 2026-06 · 13 (35)

DOI: 10.1002/advs.202508754 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 24.10.2025. Verfasst von Yan Sun und 23 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai, 200444, China. Hauptthemen laut MEDLINE: Mesothelioma, Malignant, Mesothelin, Immunotherapy, Adoptive, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of the PRC, National Key Research Plan, National key R&D program of China, Natural Science Foundation of Beijing Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant mesothelioma (MM) is an aggressive and currently incurable cancer with limited therapeutic options. Due to the high expression of mesothelin in this cancer, anti‐PD‐1 nanobody‐armored mesothelin‐targeting CAR‐T (NAC‐T) cells are developed. Based on the enhanced anti‐tumor activity observed in preclinical in vitro and in vivo studies, a first‐in‐human clinical trial is initiated. Eleven patients with malignant mesothelioma who have progressed after standard therapies receive intravenous infusions of 5–20 × 10 6 per kg NAC‐T cells following lymphodepletion. The treatment is well tolerated, with no dose‐limiting toxicity observed. The overall response rate is 63.6%, including one complete response, and the disease control rate is 100%. The median progression‐free survival is 5.0 months, and the median overall survival is 25.6 months. Moreover, T cell receptor and single‐cell sequencing analyses in patients with varying responses revealed specific clonal expansion of T cell subtypes and enhanced reactivity to tumor‐associated antigens. These findings suggest that NAC‐T cell therapy represents a promising therapeutic strategy for patients with malignant mesothelioma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mesothelioma, MalignantMesothelinImmunotherapy, AdoptiveProgrammed Cell Death 1 ReceptorReceptors, Chimeric AntigenMesotheliomaHumansFemaleMaleMiddle AgedAnimalsAged

Stichwörter der Autor:innen

CAR‐TNAC‐Tfirst‐in‐human studymalignant mesothelioma

Substanzen

MesothelinMSLN protein, humanProgrammed Cell Death 1 ReceptorReceptors, Chimeric AntigenPDCD1 protein, human

Autor:innen und Institutionen

  • School of Medicine, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai, 200444, China.
  • Shanghai Cell Therapy Group Co. Ltd, Shanghai, 201805, China.
  • State Key Laboratory of Molecular Biology, Shanghai Science Research Center, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Univers…
  • Department of Oncology, Shanghai Tenth People's Hospital, Tongji University Cancer Center, Tongji University, Shanghai, 200072, China.
  • Department of Oncology, Department of Gynecological Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
  • Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021, China.

ORCID-Profile: Jie Wang

Förderung

  • Ministry of Science and Technology of the PRC, National Key Research Plan
  • National key R&D program of China
  • Natural Science Foundation of Beijing Municipality
  • Beijing Nova Program
  • Shanghai Pilot Program for Basic Research - Chinese Academy of Sciences, the Shanghai Branch
  • CAS Young Scientists in Basic Research Program

Zitieren

APA

Sun, Y., Yang, H., Xu, Q., Li, X., Lou, J., Duan, J., Xu, J., Liu, Z., Xia, Y., Lin, Z., Li, L., Sun, D., Li, J., Liu, T., Guo, J., Xu, W., Zhu, W., Liu, Y., Sun, B., …, & Wang, J. (2026). Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies. Advanced Science, 13(35). https://doi.org/10.1002/advs.202508754

Vancouver

Sun Y, Yang H, Xu Q, Li X, Lou J, Duan J, et al. Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies. Advanced Science. 2026;13(35). doi:10.1002/advs.202508754

BibTeX
@article{Sun2026,
  author = {Sun, Yan and Yang, Haochen and Xu, Qing and Li, Xingya and Lou, Jinxing and Duan, Jianchun and Xu, Jiachen and Liu, Zhuqing and Xia, Yong and Lin, Zhicai and Li, Linlin and Sun, Dan and Li, Jiaguo and Liu, Tao and Guo, Jun and Xu, Wenfeng and Zhu, Weimin and Liu, Yi and Sun, Boyang and Zhong, Jia and Rong, Lijie and Qian, Qijun and Xu, Chenqi and Wang, Jie},
  title = {Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies},
  journal = {Advanced Science},
  year = {2026},
  volume = {13},
  number = {35},
  doi = {10.1002/advs.202508754}
}
Kostenlos starten →